M&A Deal Summary

NeoGenomics Acquires Inivata

On May 5, 2021, NeoGenomics acquired life science company Inivata for 390M USD

Acquisition Highlights
  • This is NeoGenomics’ 1st transaction in the Life Science sector.
  • This is NeoGenomics’ largest (disclosed) transaction.
  • This is NeoGenomics’ 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2021-05-05
Target Inivata
Sector Life Science
Buyer(s) NeoGenomics
Deal Type Add-on Acquisition
Deal Value 390M USD
Advisor(s) Perella Weinberg Partners (Financial)
K&L Gates (Legal)

Target

Inivata

Cambridge, United Kingdom
Inivata is a liquid biopsy company with its InVision platform that unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response, and detect relapse. Inivata's technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst-Lung is commercially available internationally and through NeoGenomics in the US. It offers competitive sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR assay - allowing the highly sensitive detection of residual disease and recurrence - which has been granted Breakthrough Device Designation by the US FDA.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

NeoGenomics

Fort Myers, Florida, United States
Category Company
Founded 2001
Sector Life Science
Employees2,100
Revenue 592M USD (2023)
DESCRIPTION

NeoGenomics is a clinical laboratory that specializes in cancer genetics diagnostic testing. The company’s testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. NeoGenomics was founded in 2001 and is based in Fort Myers, Florida.

DEAL STATS #
Overall 5 of 6
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 4 of 5
Country (United Kingdom) 1 of 2
Year (2021) 2 of 3
Size (of disclosed) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-24 Trapelo Health

Grand Rapids, Michigan, United States

Trapelo Health is a health information services company helping community oncologists incorporate molecular oncology into their practice. Trapelo Health was founded in 2009 and is based in Grand Rapids, Michigan.

Buy $65M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-01 Delf

Wirral, United Kingdom

Delf is a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products. Delf offers a wide range of animal hygiene and specialty chemical products. Delf is a select member of the Iodine Registration Group (IRG), allowing it to supply Article 95 PVP-iodine and iodine-based biocidal products to the UK and European Union animal hygiene markets. Delf was founded in 1928 and is based in Wirral, United Kingdom.

Buy -
Mergr

Product

Company

Legal